PLEUROPULMONARY SYNOVIAL SARCOMA: PRESENTATION OF AN EXCEPTIONAL CASE

Valdiviezo Allauca Nataly Sofia; Chavez Berrones Mayra Silvana; Viviana Karina Moyano Paz y Mino; Gabriela Paulina Valle Pazmino; Alexis Santiago Mejia Arias; Maria Belen Pinduisaca Verdugo

Volume : IX, Issue : V, May - 2020

PLEUROPULMONARY SYNOVIAL SARCOMA: PRESENTATION OF AN EXCEPTIONAL CASE

Valdiviezo Allauca Nataly Sofia, Chavez Berrones Mayra Silvana, Viviana Karina Moyano Paz Y Mino, Gabriela Paulina Valle Pazmino, Alexis Santiago Mejia Arias, Maria Belen Pinduisaca Verdugo

Abstract :

Pleuropulmonary synovial sarcoma (SSPP) is a morphologically, clinically, and genetically distinct entity and can be seen in any location. It is a mesenchymal spindle cell tumor with variable epithelial differentiation. There is no standardized therapy, generally the treatment is surgical. We present the case of a 40-year-old patient who presents with nonspecific symptoms and an imaging study reveals a pleural effusion, without response to treatment. Extension, paraclinical and open lung biopsy studies were performed, which reported positive for malignancy and immunohistochemical studies diagnosed monophasic synovial sarcoma. Despite adjuvant treatment, it evolves unfavorably and dies. Objective: Learn about Pleuropulmonary Synovial Sarcoma through the presentation of an exceptional case, so that readers are trained to identify the key points of the pathology (main epidemiological, clinical and pathological characteristics) despite its rare presentation. Method: This is a retrospective study of monophasic pleuropulmonary synovial sarcoma, emphasizing its clinical, radiological and histological characteristics. Conclusi�n: SSPP is an extremely rare primary lung tumor with a description based on a limited number of cases. The diagnosis can only be established after clinical and imaging studies have ruled out any other possible location that justifies lung extension. Likewise, a detailed immunohistochemical study is required for its definitive diagnosis. Treatment is surgical and its prognosis is poor with an overall survival rate of 50% at 5 years.